CYSTETIC MEDICINES
Cystetic Medicines develops a treatment that potentially could help people with cystic fibrosis (CF), regardless of genetic mutation.
CYSTETIC MEDICINES
Industry:
Biotechnology Genetics Health Care
Founded:
2019-01-01
Status:
Active
Total Funding:
25 M USD
Similar Organizations
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Founder
Investors List
Illinois Ventures
Illinois Ventures investment in Funding Round - Cystetic Medicines
Deerfield
Deerfield investment in Funding Round - Cystetic Medicines
More informations about "Cystetic Medicines"
Company - Cystetic Medicine
About cystetic Medicines One simple therapy for allof the final 10% cystetic Medicines exists to bring accessible treatment to every person with cystic fibrosis—especially those who have …See details»
Cystetic Medicines - Crunchbase Company Profile
Organization. Cystetic Medicines . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. About. Cystetic Medicines develops a treatment that potentially could help people with cystic …See details»
Cystetic Medicines - Deerfield
Cystetic Medicines is a Deerfield portfolio company.See details»
Cystetic Medicines - PitchBook
Cystetic Medicines General Information Description. Developer of a cystic fibrosis drug designed to provide a new way to treat the disease. The company specializes in creating novel inhaled …See details»
First CF patient dosed with molecular prosthetic CM001
Nov 2, 2023 The first person with cystic fibrosis (CF) has been dosed with CM001, an experimental inhaled therapy being developed by Cystetic Medicines to treat all people with …See details»
Cystetic Medicines begins Phase 1 trial of ‘molecular prosthetics’ …
Jul 1, 2023 Cystetic Medicines, a company that makes small-molecule channels to be used as molecular prosthetics for the cystic fibrosis transmembrane conductance regulator (CFTR) …See details»
Cystetic Medicines - Funding, Financials, Valuation & Investors
Cystetic Medicines develops a treatment that potentially could help people with cystic fibrosis (CF), regardless of genetic mutation. Search Crunchbase. ... How much funding has this …See details»
Patients and Families - Cystetic Medicine
Cystetic Medicines clinical trials. cystetic Medicines is launching phase 1 clinical trials with their first clinical candidate, CM001, in the spring of 2023. A phase 2 clinical trial will follow as soon as possible thereafter. The phase 2 clinical trial …See details»
Company co-founded by Carle Illinois faculty
A research team led by Marty Burke, associate dean of research at Carle Illinois College of Medicine, in collaboration with Mike Welsh and his team at the University of Iowa, has …See details»
cystetic Medicines Initiates Phase 1 Clinical Trial of a Molecular ...
Jun 26, 2023 "The initiation of our Phase 1 trial for CM001 represents an important step forward in our mission to find a treatment for everyone with CF, especially the final 10 percent of …See details»
cystetic Medicines Initiates Phase 1 Clinical Trial of a Molecular ...
Jun 26, 2023 cystetic Medicines was co-founded in 2020 by Burke, a chemist at the University of Illinois at Urbana-Champaign, and Michael Welsh, M.D., a physician-scientist at the University …See details»
cystetic Medicines Initiates Phase 1 Clinical Trial of a Molecular ...
Jun 26, 2023 cystetic Medicines is a clinical-stage biotechnology company pioneering the development of small molecule anion channel prosthetics or "molecular prosthetics" to restore …See details»
Dosing to Begin in Phase 1 Trial of CF Experimental Drug CM001
Jun 26, 2023 The first healthy volunteer has been dosed with CM001, a molecular prosthetic for missing or dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein …See details»
Cystetic Medicines Doses First Person with Cystic Fibrosis in Phase …
Jun 26, 2023 CHAMPAIGN, Ill., Oct. 30, 2023 /PRNewswire/ — cystetic Medicines, Inc., a clinical-stage biotechnology company developing small molecule channels that serve as …See details»
Cystetic Medicines doses first person | C&EN Global Enterprise
Jul 3, 2023 Cystetic Medicines, a company that makes small-molecule channels to be used as molecular prosthetics for the cystic fibrosis transmembrane conductance regulator (CFTR) …See details»
CYSTETIC MEDICINES DOSES FIRST PERSON WITH CYSTIC …
Oct 30, 2023 cystetic Medicine to present CM001 Phase 1 Single Ascending Dose Data at North American Cystic Fibrosis Conference Nov. 3, 2023. CHAMPAIGN, Ill., Oct. 30, 2023 …See details»
First Patient Dosed With CM001 in Phase 1 CF Trial - Rare Disease …
Oct 30, 2023 The first patient with cystic fibrosis (CF) has been dosed with investigational inhalable small molecule therapy CM001 in a phase 1 clinical trial, Cystetic Medicines …See details»
Our Approach - Cystetic Medicine
Approach Simplicity. Accessibility. Breath. Stopgap measures like antibiotics, anti-inflammatory drugs, chest percussion, and osmotic agents can help mitigate symptoms of cystic fibrosis, …See details»
CYSTETIC MEDICINES DOSES FIRST PERSON WITH CYSTIC …
Oct 30, 2023 cystetic Medicines will also present both clinical (Phase 1 Part A – SAD in healthy volunteers) and preclinical data on CM001 via two posters at the conference: Poster #255 …See details»